Me-PCR and DHPLC: 77.3% sens., 89.6% spec., 85.1% concordance between cfDNA (me-PCR and DHPLC) and tissue (ARMS)Response to TKI:In tumor tissue: Objective response rate (ORR) of 69.4% for patients with EGFR mutations; ORR of 13.0% for patients without EGFR mutationsIn plasma cfDNA: ORR of 64.5% for patients with EGFR mutations; ORR of 28.6% for patients without EGFR mut. The gene discussed is EGFR; the disease is neoplasm.